<DOC>
	<DOCNO>NCT01389414</DOCNO>
	<brief_summary>This multi-centre phase II , open-label , randomize ( 1:1 ) , parallel-arm , study panitumumab combination chemotherapy ( P-GEMOX ) versus chemotherapy alone ( GEMOX ) . Eligible subject enrol randomized receive first-line combination therapy consist panitumumab GEMOX ( experimental arm ) GEMOX alone ( control arm ) .The ame Stuy evaluate clinical activity P-GEMOX ( Panitumumab GEMOX ) combination compare GEMOX alone patient previously untreated surgically unresectable metastatic biliary tract carcinoma ( KRAS wild-type ) To evaluate safety profile P-GEMOX combination ; ass objective response rate ; ass overall survival ; study correlation biomarkers activity efficacy .</brief_summary>
	<brief_title>Panitumumab Plus Gemcitabine Oxaliplatin ( GEMOX ) Versus GEMOX Alone Treat Advanced Biliary Tract Adenocarcinoma</brief_title>
	<detailed_description>Study Phase : Phase II , Open-label , Randomized Indication : First line treatment advance intrahepatic cholangiocarcinoma extrahepatic biliary adenocarcinoma include gallbladder . Primary Objective : To evaluate clinical activity Panitumumab GEMOX ( P-GEMOX ) combination compare GEMOX alone patient previously untreated surgically unresectable metastatic biliary tract carcinoma ( KRAS wild-type ) . Secondary Objectives : To evaluate safety profile P-GEMOX combination ; ass objective response rate ; ass overall survival ; study correlation biomarkers activity efficacy . Study Design : Multi-centre phase II , open-label , randomize ( 1:1 ) , parallel-arm , study panitumumab combination chemotherapy ( P-GEMOX ) versus chemotherapy alone ( GEMOX ) . Eligible subject enrol randomized receive first-line combination therapy consist panitumumab GEMOX ( experimental arm ) GEMOX alone ( control arm ) . Prior study entry order confirm eligibility , investigator review relevant clinical document include exist radiological image ensure subject previously untreated , unresectable biliary tract adenocarcinoma include gallbladder . Treatment assignment do centrally via Interactive Voice Response System ( IVRS ) , use permuted-block randomization stratify accord ECOG performance status ( PS ) ( 0 1 v 2 ) , site primary tumor ( intrahepatic cholangiocarcinoma v extrahepatic biliary carcinoma include gallbladder ) . Panitumumab administer intravenous ( IV ) infusion dose 6 mg/kg every two week ( Q2W ) . GEMOX chemotherapy administer administration panitumumab Q2W . Each patient treat maximum 12 cycle disease progression ( PD ) , unacceptable toxicity , patient 's refusal . Patients experimental arm without tumor progression end chemotherapy ( 12 GEMOX complete interruption unacceptable toxicity chemotherapy ) continue panitumumab 6 mg/kg Q2W tumor progression . Following documentation progressive disease patient followed-up survival . Subjects evaluate tumor progression every 8 week + 1 week . Tumor response assessment perform Investigator use revise Response Evaluation Criteria Solid Tumors ( RECIST ) guideline , version 1.1 . Subjects symptoms suggestive PD evaluate tumor progression time symptom occur . Endpoints : Primary Endpoint : Progression-free survival ( PFS ) , define time randomization evidence progression ( RECIST , vers.1.1 ) , death , last radiographic assessment absence PFS event . Secondary Endpoints : Objective response rate ( RECIST , vers.1.1 ) ; Overall survival ; Safety , define incidence severity adverse event ( Aes ) , significant laboratory change , change vital sign , incidence concomitant medication , change baseline time ECOG performance status , incidence dose adjustment treatment period , incidence treatment limit toxicity ( TLT ) . Exploratory Endpoints : Investigation potential correlation activity combination regimen panitumumab GEMOX ( P-GEMOX ) molecular marker . Depending availability tumor tissue , biomarkers analyze follow priority : EGFr expression , nucleotide change EGFr BRAF cancer gene , mutation gene involve activation EGFr pathway ; EGFr gene amplification ) . Sample Size : Approximately 88 subject Investigational Product Dosage Administration : Panitumumab administer 60 minute +/- 15 minute IV infusion , prior administration chemotherapy , dose 6 mg/kg day 1 cycle . Gemcitabine 1000mg/sqm administer intravenous infusion accordance hospital guideline administration Gemcitabine . Gemcitabine reconstitute administer 1-hour infusion day 1 cycle . Oxaliplatin 100mg/sqm administer intravenous infusion accordance hospital guideline administration Oxaliplatin . Oxaliplatin reconstitute administer 2-hour infusion day 2 cycle . Dose Regimen : Arm A : panitumumab 6 mg/kg administer 60 minute +/- 15 minute day 1 follow Gemcitabine 1000mg/sqm administer intravenous infusion 1-hour infusion day 1 cycle . Oxaliplatin 100mg/sqm administer intravenous infusion 2-hour infusion day 2 cycle . Arm B : Gemcitabine 1000mg/sqm administer intravenous infusion 1-hour infusion day 1 cycle . Oxaliplatin 100mg/sqm administer intravenous infusion 2-hour infusion day 2 cycle . Statistical Considerations : This phase II design implies direct , non-definitive , `` screen '' comparison experimental therapeutic approach randomize standard-treatment control arm , within trial moderate sample size . Assuming accrual time 24 month follow-up time 12 month , account 10 % loss follow-up arm , total sample 88 patient expected yield necessary number event accrual rate constant . The log-rank analysis stratify ECOG PS ( 0 1 v 2 ) , site primary tumor ( ie . intrahepatic cholangiocarcinoma v extrahepatic biliary tract carcinoma include gallbladder ) .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically document surgically unresectable metastatic biliary tract adenocarcinoma ( KRAS wildtype ) include gallbladder either diagnosis relapsing surgery . Documented KRAS status either primary tumor metastasis . KRAS test perform per center procedure ( centralized analysis require ) . Availability tumor biopsy study tumor biomarkers potentially involved response/resistance mechanism . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 2 Estimated life expectancy least 3 month . Adequate bone marrow , hepatic , renal function determine within 2 week prior start therapy , define : absolute neutrophil count ( ANC ) ≥ 1.5 x 10E9 cells/L platelet count ≥ 100 x 10E9 cells/L total hemoglobin &gt; 9.0 g/dL total bilirubin &lt; 2.0 x institutional upper limit normal ( ULN ) alanine aminotransferase ( ALT ) , aspartate transaminase ( AST ) &lt; 2.5 x ULN alkaline phosphatase &lt; 3.0 x ULN creatinine &lt; 1.5 X ULN magnesium ≥ LLN calcium ≥ LLN Voluntary , write date informed consent . Any previous chemotherapy target therapy . Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol . Coexisting malignancy , except basal squamous cell carcinoma skin solid tumor curatively treat evidence disease ≥ 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>biliary</keyword>
	<keyword>gallbladder</keyword>
	<keyword>intrahepatic</keyword>
	<keyword>extrahepatic</keyword>
</DOC>